Holen Sie sich die Stockscreener-App
17.82
3.66%
0.63
Handel nachbörslich:
17.36
-0.46
-2.58%
Schlusskurs vom Vortag:
$17.19
Offen:
$17.05
24-Stunden-Volumen:
798.90K
Relative Volume:
0.50
Marktkapitalisierung:
$102.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-1.5826
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
+13.43%
1M Leistung:
-40.14%
6M Leistung:
+7.67%
1J Leistung:
-96.52%
1-Tages-Spanne:
$16.83
$18.74
1-Wochen-Bereich:
$14.33
$18.74
52-Wochen-Spanne:
$7.31
$672.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Vergleichen Sie TNXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
17.82 | 102.89M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Holding CorpDiscontinued Enrollment And Terminated Phase 2 Catalyst StudySEC Filing - marketscreener.com
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data - citybuzz -
Tonix reports promising results for mpox vaccine TNX-801 By Investing.com - Investing.com South Africa
Tonix reports promising results for mpox vaccine TNX-801 - Investing.com
Tonix Pharmaceuticals (TNXP) Unveils Promising Results for Single-Dose Mpox Vaccine | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 - The Manila Times
Tonix Pharmaceuticals Presented Data on Potential Mpox - GlobeNewswire
Single-Dose Mpox Vaccine Breakthrough: Complete Protection for Immunocompromised Patients in Latest Trial - Stock Titan
Tonix Pharma Presents Promising Vaccine Data at Congress - TipRanks
Tonix Pharmaceuticals (TNXP) Falls Despite Market Upturn - GuruFocus
Tonix Pharmaceuticals (TNXP) to Present at World Vaccine Congress - GuruFocus
When the Price of (TNXP) Talks, People Listen - news.stocktradersdaily.com
Tonix Pharmaceuticals Announces Oral Presentation And Panel Participation At The World Vaccine Congress Washington 2025 - marketscreener.com
Tonix Pharmaceuticals Announces Oral Presentation and Panel - GlobeNewswire
Major Breakthrough: Tonix Unveils Single-Dose Mpox Vaccine Data at Leading Global Conference - Stock Titan
Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday? - MSN
Tonix and Makana partner on xenotransplantation research By Investing.com - Investing.com India
Tonix Pharmaceuticals and Makana Therapeutics Announce Collabora - GuruFocus
Tonix and Makana partner on xenotransplantation research - Investing.com
Tonix Pharmaceuticals and Makana Therapeutics Announce - GlobeNewswire
Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix'S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana'S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies - marketscreener.com
Revolutionary Xenotransplantation Breakthrough: Tonix and Makana Join Forces to Combat Organ Failure - Stock Titan
Tonix Pharmaceuticals launches :TONIX ONE™ A digital breakthrough in migraine management - Proactive financial news
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting - GlobeNewswire
Game-Changing Fibromyalgia Treatment Achieves Phase 3 Success, FDA Decision Looms - Stock Titan
(TNXP) Investment Analysis - news.stocktradersdaily.com
Peering Into Tonix Pharmaceuticals's Recent Short Interest - Benzinga
TNXP: No AdCom Required for TNX-102 SL NDA… - Yahoo Finance
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference - GlobeNewswire
Tonix Pharmaceuticals Reveals 5 Major Catalysts: FDA Decision, DoD Contract, and Breakthrough Therapies - Stock Titan
Tonix Pharmaceuticals launches migraine management platform By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals Launches TONIX ONE™, a - GlobeNewswire
Tonix Pharma stock rises following TONIX ONE launch By Investing.com - Investing.com South Africa
Tonix Pharma stock rises following TONIX ONE launch - Investing.com Australia
Tonix Pharmaceuticals launches migraine management platform - Investing.com
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition - GlobeNewswire
Game-Changing Digital Platform Transforms How Patients Track and Treat Migraines - Stock Titan
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Lat - PharmiWeb.com
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year - ACCESS Newswire
Revolutionary Non-Opioid Pain Drug Could Transform Fibromyalgia Treatment by 2025 - Stock Titan
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - Bluefield Daily Telegraph
(TNXP) Long Term Investment Analysis - Stock Traders Daily
Tonix Pharmaceuticals Announces Presentation at the - GlobeNewswire
Fast-Tracked Fibromyalgia Treatment: Tonix Showcases Breakthrough Pain Drug Data Before FDA Decision - StockTitan
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years - Seeking Alpha
Noble Capital maintains Outperform on Tonix Pharma, $70 target By Investing.com - Investing.com South Africa
Noble Capital maintains Outperform on Tonix Pharma, $70 target - Investing.com
Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic (TNXP) - Seeking Alpha
Pharma Frenzy: Volatility Ignites Biotech Sector - Benzinga
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):